Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ジキニンファーストネオCZ
- Development stage
- Unknown
- Lead developer
- Zenyaku Kogyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ジキニンファーストネオCZ (Jikinin First Neo CZ) is a multi-symptom over-the-counter (OTC) cold medication developed and marketed by Zenyaku Kogyo (Zenyaku Holdings) in Japan. It is formulated as a combination product to alleviate various symptoms associated with the common cold, including fever, sore throat, cough, and nasal congestion. The formulation typically contains seven active ingredients: ibuprofen (analgesic and antipyretic), tranexamic acid (anti-inflammatory for throat pain), bromhexine hydrochloride (mucolytic/expectorant), dihydrocodeine phosphate (antitussive), dl-methylephedrine hydrochloride (bronchodilator), chlorpheniramine maleate (antihistamine), and anhydrous caffeine. It is classified as a Designated Class 2 OTC drug in Japan and is administered orally, usually in tablet form.
- Brand names
- ジキニンファーストネオCZJikinin First Neo CZ
02
Targets
TUBB (Tubulin (alpha and beta subunits))HRH1 (Histamine H1 Receptor)MOR (Mu opioid receptor)AR (Adrenergic receptors)ADOR (Adenosine receptors)COX
Beyond the preview
Go deeper on ジキニンファーストネオCZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ジキニンファーストネオCZ.